New Peer-Reviewed Study Finds COVID Booster Shots Increase Myocarditis Risk

This article originally appeared on The Epoch Times and was republished with permission.

Guest post by Naveen Athrappully

Booster vaccination against COVID-19 is linked to a higher risk of heart inflammation among adolescents, according to a recent study using data from several Nordic nations.

The peer-reviewed study, published in the European Heart Journal on Feb. 15, evaluated the risk of myocarditis among 12- to 39-year-olds after receiving COVID-19 mRNA booster vaccination. Myocarditis refers to an inflammation of the heart muscle myocardium. The study analyzed data from 8.9 million young adults from four nations: Denmark, Finland, Norway, and Sweden.

In total, 1,533 cases of myocarditis were identified with the study concluding that the “booster dose is associated with increased myocarditis risk in adolescents and young adults.”

Among males, a third dose of the Pfizer or Moderna vaccine was associated with an “increased incidence rate of myocarditis” within 28 days of inoculation compared to a longer period after the second dose.

The study noted that the association of myocarditis with COVID-19 mRNA vaccines has appeared “strongest in male adolescents and younger males and after the second dose.”

The study was authored by 12 experts from the Norwegian Institute of Public Health, Swedish Medical Products Agency, Statens Serum Institut, and the Finnish Institute for Health and Welfare.

Significant Spike in Cases

Cases of myocarditis among vaccinated individuals in the United States spiked within the first year of the COVID-19 vaccination campaign, according to a study published in late January that looked at data from the Vaccine Adverse Event Reporting System (VAERS).

“We found the number of myocarditis reports in VAERS after COVID-19 vaccination in 2021 was 223 times higher than the average of all vaccines combined for the past 30 years. This represented a [2,500 percent] increase in the absolute number of reports in the first year of the campaign when comparing historical values prior to 2021,” the U.S. study said.

Roughly 50 percent of myocarditis cases occurred among youths and 69 percent of affected individuals were males. Out of a total of 3,078 COVID-19 vaccine-induced myocarditis cases as of August 2023, 76 percent resulted in emergency care and hospitalization, and 3 percent died.

New studies are being published looking at reducing myocarditis risk when vaccinating adolescents against COVID-19, appearing to confirm the fact that such a risk exists for the shots.

A Feb. 14 study in the journal Vaccines found that extending the interval between the first and the second dose of COVID-19 mRNA vaccines leads to a 66 percent “lower risk of incident carditis among adolescents.”

Carditis is the general term for inflammation of the heart.

The study referred to adolescents as a “vulnerable population” while pointing out that “previous studies indicate an increased carditis risk among adolescents following the two-dose messenger RNA COVID-19 vaccine.”

Read the full story at The Epoch Times.